Heart Failure Clinical Trial

Prospective Evaluation of the StatusFirstâ„¢ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

Summary

The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where said samples are collected in EDTA and Li-Hep anticoagulant tubes and measured by the StatusFirstâ„¢ CHF NT-proBNP device in conjunction with the DXpressTM Reader in a laboratory setting.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have clinically confirmed heart failure (NYHA class I-IV) or have presented to an emergency room or clinic with signs, symptoms and/or risk factors suggestive of heart failure, OR
Be non-CHF controls greater than 45 years of age with no history of heart failure or cardiovascular disease.

Exclusion Criteria:

Be 45 years of age or younger

Study is for people with:

Heart Failure

Estimated Enrollment:

450

Study ID:

NCT00734045

Recruitment Status:

Completed

Sponsor:

Nanogen, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

US Department of Veteran's Affairs
San Diego California, 92161, United States
San Francisco General Hospital
San Francisco California, 94110, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

450

Study ID:

NCT00734045

Recruitment Status:

Completed

Sponsor:


Nanogen, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider